Journey Medical said on Monday the U.S. Food and Drug Administration has approved its drug for the treatment of a long-term ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

NeurAxis (NYSE:NRXS) announced today that the FDA granted an expanded 510(k) clearance for its IB-Stim non-implanted nerve ...

SAN ANTONIO, Tx - Cancer patients need a lot of drugs—immunotherapies, chemotherapies, and anti-infectives. But new research at ObesityWeek® on Nov. 3, 2024, shows clinicians may not have all the ...

FDA's Human Foods Program released its 2025 Priority Deliverables today, which details the primary focuses for its first year ...

An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the ...

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...

You may have heard about — or maybe even experienced — the short-term side effects of Ozempic® — such as nausea, vomiting, ...

Purpose: The revised prescription drug labeling developed by the Food and Drug Administration (FDA) is described. Summary: A new FDA final rule, "Requirements on Content and Format of Labeling for ...

("NeurAxis,” or the "Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, ...

A viral Facebook post questioned if Breyers was truly serving up real ice cream. Here's how the product compares to the FDA's ...

Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic ...